- Home
- AVNS vs EYPT Comparison
AVNS vs EYPT Comparison
Compare AVNS & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVNS | EYPT |
|---|---|---|
| Founded | 2014 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2014 | 2005 |
Fundamental Metrics
Financial Performance| Metric | AVNS | EYPT |
|---|---|---|
| Price | $25.10 | $13.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $31.80 |
| AVG Volume (30 Days) | ★ 1.0M | 843.1K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.59 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $701,200,000.00 | $7,539,000.00 |
| Revenue This Year | $3.28 | N/A |
| Revenue Next Year | $4.23 | $3,115.57 |
| P/E Ratio | $225.50 | ★ N/A |
| Revenue Growth | ★ 1.95 | N/A |
| 52 Week Low | $9.30 | $7.35 |
| 52 Week High | $24.91 | $19.11 |
Technical Indicators
Market Signals| Indicator | AVNS | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 86.18 | 49.05 |
| Support Level | $24.60 | $12.58 |
| Resistance Level | N/A | $13.32 |
| Average True Range (ATR) | 0.11 | 0.73 |
| MACD | -0.26 | 0.10 |
| Stochastic Oscillator | 59.57 | 68.76 |
Price Performance
Historical ComparisonAbout AVNS Avanos Medical Inc.
Avanos Medical Inc is a medical technology company engaged in the development and commercialization of products for pain management and patient care. The company has two reportable segments: Specialty Nutrition Systems and Pain Management and Recovery. The Specialty Nutrition Systems segment provides enteral feeding and neonatal products. The Pain Management and Recovery segment offers surgical pain and recovery products, including pain pumps and radiofrequency ablation solutions for the treatment of chronic pain.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.